Tenax Therapeutics, Inc. (TENX)Healthcare | Biotechnology | Chapel Hill, United States | NasdaqCM
1.44 USD
-0.07
(-4.675%) ⇩
(Oct. 16, 2026, 9:50 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 5:46 a.m. EDT
Tenax Therapeutics presents a classic biotech value trap where the market has priced out the company entirely due to a catastrophic multi-year decline. Despite a recent 116% annual rebound, the asset has lost 99.99% of its value over the last nine years, a structural deterioration that dwarfs any single-year recovery. The balance sheet is fragile for a biotech, burning through cash with negative free cash flow and no revenue, while the lack of dividends confirms its speculative nature. While analysts project massive upside, the options market tells a different story: heavy put buying suggests investors are betting against the stock holding up, fearing the clinical trial data coming in August will fail to reverse the long-term trend. The statistical forecast model is useless here given the extreme volatility and low reliability, so the decision rests on whether the upcoming trial can truly reset the valuation floor. Until then, the risk-reward profile remains skewed heavily toward capital preservation rather than growth. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.062022 |
| AutoETS | 0.063960 |
| MSTL | 0.172886 |
| AutoTheta | 0.448983 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 1.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.037 |
| Excess Kurtosis | 1.61 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 53,867,984 |
| Forward P/E | -0.96 |
| Beta | 0.92 |
| Website | https://www.tenaxthera.com |
As of Oct. 10, 2026, 5:46 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in deep out-of-the-money puts (strikes $10 and $7.50) expiring in late 2027 and early 2028, suggesting a fear of a prolonged decline or a failed catalyst. Conversely, call activity is concentrated in extremely distant strikes ($15-$30) with negligible volume, indicating a lack of serious bullish conviction despite the wide analyst price targets.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.77412117 |
| Address1 | 101 Glen Lennox Drive |
| Address2 | Suite 300 |
| All Time High | 21,600,000.0 |
| All Time Low | 1.31 |
| Ask | 6.0 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.9 - Buy |
| Average Daily Volume10 Day | 2,256,680 |
| Average Daily Volume3 Month | 5,600,817 |
| Average Volume | 5,600,817 |
| Average Volume10Days | 2,256,680 |
| Beta | 0.917 |
| Bid | 1.45 |
| Bid Size | 1 |
| Board Risk | 4 |
| Book Value | 2.193 |
| City | Chapel Hill |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.4394 |
| Current Ratio | 15.07 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.52 |
| Day Low | 1.43 |
| Display Name | Tenax Therapeutics |
| Dividend Date | 1,519,603,200 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | -31,480,240 |
| Eps Current Year | -1.45222 |
| Eps Forward | -1.5 |
| Eps Trailing Twelve Months | -1.48 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.3172 |
| Fifty Day Average Change | -0.8778 |
| Fifty Day Average Change Percent | -0.37881926 |
| Fifty Two Week Change Percent | -77.41212 |
| Fifty Two Week High | 19.4 |
| Fifty Two Week High Change | -17.9606 |
| Fifty Two Week High Change Percent | -0.92580414 |
| Fifty Two Week Low | 1.31 |
| Fifty Two Week Low Change | 0.12940001 |
| Fifty Two Week Low Change Percent | 0.09877864 |
| Fifty Two Week Range | 1.31 - 19.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 765,466,200,000 |
| Float Shares | 30,779,316 |
| Forward Eps | -1.5 |
| Forward P E | -0.9596 |
| Free Cashflow | -24,048,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Fullday Change | -0.07060003 |
| Fullday Change Percent | -4.675499 |
| Fullday Price | 1.4394 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0018000001 |
| Held Percent Institutions | 1.15124 |
| Implied Shares Outstanding | 37,423,917 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,704,240,000 |
| Last Split Factor | 1:80 |
| Long Business Summary | Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina. |
| Long Name | Tenax Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 53,867,984 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_389766 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -64,863,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 71,666,801 |
| Number Of Analyst Opinions | 9 |
| Open | 1.5 |
| Operating Cashflow | -46,029,000 |
| Operating Margins | 0.0 |
| Overall Risk | 5 |
| Peg Ratio | 1.44 |
| Phone | 919 855 2100 |
| Previous Close | 1.51 |
| Price Eps Current Year | -0.99117213 |
| Price Hint | 4 |
| Price To Book | 0.6563611 |
| Profit Margins | 0.0 |
| Quick Ratio | 14.614 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.9 |
| Region | US |
| Regular Market Change | -0.07060003 |
| Regular Market Change Percent | -4.675499 |
| Regular Market Day High | 1.52 |
| Regular Market Day Low | 1.43 |
| Regular Market Day Range | 1.43 - 1.52 |
| Regular Market Open | 1.5 |
| Regular Market Previous Close | 1.51 |
| Regular Market Price | 1.4394 |
| Regular Market Time | 1,792,158,628 |
| Regular Market Volume | 236,647 |
| Return On Assets | -0.37695998 |
| Return On Equity | -0.59804 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 37,423,917 |
| Shares Percent Shares Out | 0.1919 |
| Shares Short | 7,182,126 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,276,905 |
| Short Name | Tenax Therapeutics, Inc. |
| Short Percent Of Float | 0.1935 |
| Short Ratio | 1.49 |
| Source Interval | 15 |
| State | NC |
| Symbol | TENX |
| Target High Price | 36.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 12.55556 |
| Target Median Price | 5.0 |
| Total Cash | 117,976,000 |
| Total Cash Per Share | 2.06 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.48 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.7164 |
| Two Hundred Day Average Change | -9.277 |
| Two Hundred Day Average Change Percent | -0.86568254 |
| Type Disp | Equity |
| Volume | 236,647 |
| Website | https://www.tenaxthera.com |
| Zip | 27,517 |